Botulinum toxin shows sustained, positive effects in BPH
Intraprostatic injection of botulinum toxin type A (Botox) is asafe and effective treatment in patients with symptomatic BPH thatresults in improvements in symptoms and quality of life that maypersist for up to 1 year, researchers from Taiwan said.
Intraprostatic injection of botulinum toxin type A (Botox) is a safe and effective treatment in patients with symptomatic BPH that results in improvements in symptoms and quality of life that may persist for up to 1 year, researchers from Taiwan said.
Yao-Chi Chuang, MD, of Chang Gung Memorial Hospital, Kaohsiung Medical Center, reported outcomes for 41 men treated with botulinum toxin type A. All were refractory to medication and had received no previous invasive therapy for their BPH.
Twenty-one men with a prostate volume less than 30 mL received a dose of 100 U; 20 men with larger prostates received a dose of 200 U. The injections were delivered via a transperineal approach under transrectal ultrasound guidance.
The treatment was safe and well tolerated, with no patients developing any significant local or systemic side effects attributable to the botulinum toxin. Thirty-one (76%) of the 41 men achieved more than a 30% improvement in both IPSS and QOL scores. Mean prostate volume also decreased significantly by about 15% in both dosage groups. While 12 men had no change of prostate volume, maximal flow rate still improved by more than 30% among seven (58%) of those patients. In addition, four of five men (80%) in urinary retention for more than 1 month were able to void spontaneously between 1 week and 1 month after the botulinum toxin injection.
"Further studies including a placebo-controlled arm and histological and molecular evaluation are needed to confirm the beneficial effect of botulinum toxin type A treatment for symptomatic BPH and to evaluate its mechanism," Dr. Chuang said.
Seeds vs. prostatectomy: Long- and short-term side effects differ slightly
March 15th 2007For men with prostate cancer, radiation seed implants may yield a better short-term side effect profile than surgery, but surgery may offer slightly better long-term outcomes, new research from French radiation oncologists indicates.
Brachytherapy offers high 8-year prostate Ca survival rates
February 15th 2007More than 90% of men who receive appropriate radiation dose levels with permanent radiation seed implants to treat their prostate cancer are cured of the disease 8 years after diagnosis, according to a recent study in the International Journal for Radiation Oncology Biology Physics (2007; 67:327-33).
Research on bladder tissue regeneration progresses
February 1st 2007Atlanta-Tissue engineering research has grown by leaps and bounds in the past decade and a half, yielding findings that may someday have a profound impact on the field of pediatric urology. At the 2006 American Academy of Pediatrics Section on Urology annual meeting here, several groups presented cutting-edge data on novel systems for organ generation, including research demonstrating the feasibility of generating a functioning bladder from stem cells.
Radiation therapy combination prolongs long-term cure rate in men with PCa
January 18th 2007Three-fourths of men treated with a combination of radiation seed implants and external beam radiation therapy for prostate cancer are cured of their disease 15 years following their treatment, according to a study published in the International Journal of Radiation Oncology*Biology*Physics (2007; 67:57-64).
Cystectomy outcomes: Does surgeon's age matter?
October 1st 2006Ann Arbor, MI-Surgeon age is not a significant predictor of risk of mortality after cystectomy, according to the results of a recently published study from researchers at the University of Michigan, Ann Arbor (Ann Surg 2006; 244:353-62).
